纳入心脏亚结构的保心VMAT技术用于晚期非小细胞肺癌
本研究纳入27例接受根治性放疗的IIIA/B期非小细胞肺癌患者,为同一队列重新计算27份保心(AHS)优化计划并与原标准计划比较。AHS在全部患者中可行,靶区覆盖良好且危及器官约束均满足;平均心脏剂量中位数AHS组6.71 Gy低于标准组8.18 Gy(p=0.000),心脏及亚结构多项剂量参数在标准组更差。作者认为该技术可能减少心脏事件并延长生存。
要点
- 27例IIIA/B期NSCLC患者标准计划与AHS计划配对比较,AHS全部可行。
- 平均心脏剂量中位数AHS组6.71 Gy vs 标准组8.18 Gy(p=0.000)。
- 左前降支、左心室、心脏基底部等亚结构剂量参数标准组更差。
核心结论
- 在局部晚期中心型NSCLC根治性放疗中采用AHS优化可改善心脏及心脏亚结构的剂量学参数。
- 作者认为该技术可能减少心脏事件并延长生存。
- 作者提出新的晚期NSCLC放疗临床研究应纳入心脏科评估、生物标志物及心脏亚结构勾画。
研究设计与样本
- 对27例接受根治性放疗的IIIA/B期NSCLC患者,将原有放疗计划修订并另计算27份采用AHS的新等效计划。
- 主要终点为采用心脏亚结构约束的AHS可行性;次要终点为心脏亚结构、主要危及器官剂量参数及PTV覆盖参数的组间差异。
主要发现
- AHS在全部患者中可行,靶区覆盖理想且所有强制危及器官约束均满足。
- 平均心脏剂量中位数标准计划组8.18 Gy vs AHS组6.71 Gy(p=0.000)。
- V5Gy标准组40.57% vs AHS组27.7%(p=0.000),V30Gy标准组5.39% vs AHS组3.86%(p=0.000),标准组更差。
- 心脏基底部中位剂量标准组16.97 Gy vs AHS组6.37 Gy(p=0.000),左前降支最大剂量标准组18.64 Gy vs AHS组6.05 Gy(p=0.000),左前降支V15Gy标准组11.11% vs AHS组0%(p=0.000)。
- 左心室V5Gy标准组9.55% vs AHS组0.94%(p=0.000),左心室V23Gy两组均为0.00%,最大值标准组45.68% vs AHS组6.57%(p=0.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the feasibility of active heart sparing (AHS) planning in patients with locally advanced and centrally located NSCLC receiving standard definitive radiotherapy (RT), while maintaining or improving appropriate lung, esophagus, and spinal cord constraints and planning target volume (PTV) coverage intent. METHODS AND MATERIALS: A total of 27 patients with stage IIIA/B NSCLC treated with curative intent RT were selected for this analysis. All existing radiation plans were revised and 27 further new equivalent plans were calculated using AHS for the same cohort of patients. Primary end-point was feasibility of AHS using constraints for heart substructures. The secondary end point was to calculate the difference in terms of dosimetric parameters of heart substructures and principal OARs as well as PTV-coverage parameters within the current patient group. RESULTS: AHS was feasible in the entire group of patients. An optimal coverage of the target volume was obtained and all mandatory constraints for OARs have been met. The median value of the mean heart dose (MHD) was 8.18 Gy and 6.71 Gy in the standard planning group and AHS-group, respectively (p = 0.000). Other heart parameters such as V5Gy (40.57% vs. 27.7%; p = 0.000) and V30Gy (5.39% vs. 3.86%; p = 0.000) were significantly worse in the standard planning group. The following relevant dosimetric parameters regarding heart substructures were found to be significantly worse in the standard planning group compared to the AHS-group: median dose to heart base (16.97 Gy vs. 6.37 Gy, p = 0.000), maximum dose (18.64 Gy vs. 6.05 Gy, p = 0.000) and V15Gy (11.11% vs. 0% p = 0.000) to LAD; mean dose; V5Gy (9.55% vs. 0.94%, p = 0.000) and V23Gy (0.00% vs. 0.00% maximum 45.68% vs. 6.57%, p = 0.002 to the left ventricle. CONCLUSION: Our analysis showed an improvement of dosimetric parameters of the heart and heart substructures in patients affected by locally advanced and centrally located NSCLC treated with curative RT using AHS optimization. This approach could lead to a possible reduction of heart events and a prolonged survival. New clinical studies regarding RT in advanced NSCLC should include cardiologic evaluations and biomarkers as well as the contouring of cardiac substructures.
引用
- Agolli L, Exeli AK, Schneider U, et al. Development of heart-sparing VMAT radiotherapy technique incorporating heart substructures for advanced NSCLC patients. Radiat Oncol. 2025. PMID: 40087770. doi:10.1186/s13014-025-02597-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。